Pharmacokinetic (PK) studies for RXFP1-agonists

The National Institutes of Health, Office of the Director, Office of Acquisitions, seeks in vivo pharmacokinetic studies for RXFP1-agonists, with responses due August 24, 2026. This is an unrestricted, competitive acquisition under FAR 12.603 streamlined procedures for commercial services, to be awarded on a Firm-Fixed-Price basis to the responsible offeror whose proposal represents best value.

The requirement comprises single-dose PK studies in male C57BL/6J mice with intraperitoneal administration of four test compounds at 10 mg/kg. The scope includes three animals per time point across eight sampling time points, collection of plasma, lung, liver, and heart tissues, quantitative bioanalysis of drug concentrations in all matrices, calculation of standard pharmacokinetic parameters, and delivery of electronic Excel data files and a final study report. The contractor must provide all necessary services, qualified personnel, materials, equipment, and facilities independently, with an estimated turnaround time of five working days. Period of performance runs from August 31, 2026 to August 30, 2027.

Delivery location is NIH/NCATS at 9808 Medical Center Drive, Rockville, Maryland. The NAICS code is 541380, Testing Laboratories and Services, with a small business size standard of $19.0 million. Responses must include unit and total pricing, shipping and handling costs, delivery timeframe, F.O.B. point, product or service description, Unique Entity Identifier, Taxpayer Identification Number, and business size certification. All offerors must be actively registered in SAM. Evaluation considers price, technical capability, past performance, and delivery schedule. The solicitation number is 75N98026Q00976. Point of contact is Jaddua Johnston, Contracting Specialist, at 240-569-0006 or Jaddua.Johnston@nih.gov.